ANNALS OF PLASTIC SURGERY, published by Lippincott Williams & Wilkins, is a premier academic journal dedicated to the field of plastic and reconstructive surgery. With an ISSN of 0148-7043 and an E-ISSN of 1536-3708, this journal has been a significant contributor to the surgical community since its inception in 1978, continuing to present cutting-edge research and innovations through 2024. The journal is recognized for its rigorous peer-review process and holds a respectable Q2 ranking in Surgery according to the 2023 Category Quartiles, placing it among the top journals in the field. With a Scopus rank of #215 out of 551 in Medicine - Surgery, and positioned in the 61st percentile, the ANNALS OF PLASTIC SURGERY serves as a vital resource for researchers, clinicians, and students seeking to advance their knowledge and practice in plastic surgery. This journal provides a platform for the dissemination of clinical studies, review articles, and case reports, emphasizing the importance of innovative treatments and techniques in enhancing patient outcomes.

Revista de Senologia y Patologia Mamaria, published by ELSEVIER, serves as a vital resource for researchers and practitioners in the fields of obstetrics, gynecology, oncology, and radiology. With its ISSN 0214-1582 and E-ISSN 1578-1399, the journal's scope encompasses the latest advancements and multidisciplinary approaches to breast pathology and senology. Despite its current Q4 ranking across various categories, the journal continues to contribute significantly to the academic discourse, offering a platform for rigorous peer-reviewed articles, case studies, and clinical trials. Its ongoing commitment to distributing knowledge that advances the field is essential, especially given the increasing relevance of breast health in patient care. Situated in Spain with accessible research from 2012 to 2024, the journal invites contributions that further the understanding and treatment of breast-related diseases, making it an indispensable tool for students and healthcare professionals alike, eager to enhance their expertise in this specialized area.

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.

GEBURTSHILFE UND FRAUENHEILKUNDE is a prestigious journal dedicated to the fields of Maternity, Midwifery, Obstetrics, and Gynecology, published by GEORG THIEME VERLAG KG, a reputable publisher known for its commitment to advancing medical knowledge. Established in 1947, the journal has consistently provided a platform for high-quality research and clinical studies that address current challenges and innovations in women's health. With an impact factor positioned in Q2 for Maternity and Midwifery and Q3 in Obstetrics and Gynecology, it ranks among the top journals within its field, further solidified by its Scopus rankings highlighting its influential presence. Although the journal is not open access, it remains an essential resource for academics and practitioners keen to stay informed on the latest evidence-based practices and cutting-edge research, ensuring that all stakeholders in women's healthcare can access critical insights to enhance patient outcomes.

Familial Cancer is a premier journal dedicated to advancing the understanding of hereditary cancer, published by Springer. With an ISSN of 1389-9600 and E-ISSN 1573-7292, this journal serves as an essential platform for researchers and clinicians focused on the genetic predispositions to cancer and the implications for patient care. Since its inception in 2001, Familial Cancer has built a strong reputation, being consistently ranked in the Q2 category across several key research areas including Cancer Research, Genetics, and Oncology. As of 2023, it holds significant Scopus rankings, reflecting its impactful contributions in the fields of Medicine and Genetics, with a focus on clinical applications. The journal does not currently offer Open Access, emphasizing the commitment to rigorous peer review and high-quality publications. It is vital for emerging researchers and seasoned professionals alike, providing insights into the hereditary aspects of cancer and fostering developments that can lead to better prevention and therapeutic strategies.

Breast Cancer Management is a pivotal journal in the field of oncology and radiology, published by FUTURE MEDICINE LTD. Since its transition to Open Access in 2018, the journal has aimed to democratize access to cutting-edge research focused on innovative treatments and management strategies for breast cancer. With an ISSN of 1758-1923 and an E-ISSN of 1758-1931, it provides a platform for researchers and clinicians to share findings that enhance patient care and outcomes. The journal has garnered significant attention, placing in the Q3 quartile in Oncology and Q2 in Radiology, Nuclear Medicine, and Imaging as of 2023. Positioned in the United Kingdom, its editorial focus and rigorous peer-review process ensure that it remains at the forefront of breast cancer research. As breast cancer continues to be a major health concern globally, Breast Cancer Management serves as an essential resource for advancing knowledge and fostering collaboration among professionals in this vital area of medicine.

The Breast Journal, published by Wiley-Hindawi, is a distinguished Open Access journal dedicated to the fields of internal medicine, oncology, and surgery with a particular focus on breast health and disease. Since its inception in 1995, the journal has become an essential resource for researchers and clinicians, facilitating the dissemination of high-quality research and innovative clinical practices. With an impact factor reflecting robust scholarly influence and a ranking in the Q3 quartile for both internal medicine and oncology, as well as Q2 in surgery, it showcases significant contributions that advance knowledge and improve patient outcomes. Offering unparalleled access to its articles, The Breast Journal aims to support a global audience in exploring the multifaceted challenges and breakthroughs in breast-related health, making it a vital platform for shared learning and scientific discourse.

Breast Cancer-Targets and Therapy is a leading journal in the field of oncology, published by DOVE MEDICAL PRESS LTD in New Zealand. Established as an Open Access journal in 2009, it offers a platform for researchers and healthcare professionals to disseminate innovative findings and therapeutic strategies related to breast cancer. With an impressive ranking in the Q2 category of oncology journals as of 2023, and placed at Rank #203/404 in the Scopus database, this journal facilitates the exchange of high-quality research aimed at improving patient outcomes and advancing clinical practices. Covering a wide array of topics from basic research to clinical trials, Breast Cancer-Targets and Therapy plays a crucial role in bridging the gap between scientific discovery and practical application. Researchers, professionals, and students alike will find the journal a valuable resource for the latest advancements and best practices in breast cancer treatment.

Annales de Chirurgie Plastique Esthetique is a prestigious academic journal published by Elsevier, focusing on the dynamic field of plastic and aesthetic surgery. With an ISSN of 0294-1260 and an E-ISSN of 1768-319X, this journal has been at the forefront of surgical innovation since its inception in 1983 and continues to be an essential resource for clinicians, researchers, and students involved in surgery. The journal is positioned in the Q3 quartile of the surgery category, reflecting its growing influence within the discipline, as evidenced by its Scopus rankings of #352 out of 551 in medicine and surgery. Annales de Chirurgie Plastique Esthetique aims to disseminate cutting-edge research, clinical insights, and reviews that advance the practice of plastic surgery. It fosters a platform for dialogue among professionals dedicated to improving patient outcomes through evidence-based approaches and innovative techniques. Although currently not an open-access journal, its commitment to quality and relevance positions it as an invaluable reference point within the surgical community.

The International Journal of Breast Cancer is a premier academic platform dedicated to advancing the field of breast cancer research and treatment. Published by HINDAWI LTD, this journal embraces an Open Access model since 2011, ensuring that cutting-edge research is readily accessible to all, facilitating the dissemination of knowledge across the global scientific community. With its ISSN 2090-3170 and E-ISSN 2090-3189, the journal caters to a diverse audience comprising researchers, clinicians, and students engaged in oncology and pharmacology. The journal has consistently demonstrated its relevance, classified in the Q4 quartile for Cancer Research and the Q3 quartile for both Oncology and Pharmacology in the latest rankings. It currently ranks #151/272 in the Medicine & Pharmacology category and #232/404 in Medicine & Oncology according to Scopus, showcasing its adaptive role in an evolving field. Commencing in 2013 and continuing through to 2024, the journal is positioned to be an essential resource, addressing critical topics and fostering innovative solutions for breast cancer challenges.